Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Microsoft, Amazon facing UK antitrust probe over cloud services
Pets pose a serious health threat that we've all been overlooking
Letitia James and 32 other attorneys general sue Meta for ‘harming youth’
Facebook down: Instagram and WhatsApp also facing issues amid widespread outage
Google, Meta Take on Trudeau in Proxy Fight Over Digital News Content
Musk Says X Will Offer Video and Audio Calls in Move Toward Super-App
IBM Will Buy Software Company Apptio for $4.6 Billion
MrBeast breaks own YouTube views record by 'outperforming' 'Squid Game' video in just 24 hours